Don't prescribe tiotropium for smokers with an FEV1 above 60% predicted

Primary Care Respiratory Journal

Volumn 18, Issue 2, 2009, Pages 119-120

  Enright, Paul ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE;

AIRWAY OBSTRUCTION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HUMAN; LETTER; LUNG FUNCTION; MALIGNANT ARRHYTHMIA; PRESCRIPTION; QUALITY OF LIFE; RISK FACTOR; SMOKING; SPIROMETRY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ARRHYTHMIAS, CARDIAC; BRONCHODILATOR AGENTS; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES; SMOKING; SMOKING CESSATION;

EID: 66549104871     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.3132/pcrj.2009.00014     Document Type: Letter

References (14)

1. Johansson G, Lindberg A, Romberg K, Nordstrom L, Gerken F, Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Resp J 2008;17(3):169-173 doi:10.3132/pcrj.2008.00037
2. Schermer TR, Smeele IJ, Thoonen BP, et al. Current clinical guideline definitions for airflow obstruction leads to substantial overdiagnosis of COPD in primary care. Eur Resp J 2008;32(4):945-952 Epub 2008 Jun 11.
3. Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007;147(9):633-638
4. Pinto-Plata VM, Celli-Cruz RA, Vassaux C, et al. Differences in cardiopulmonary exercise test results by ATS/ERS-GOLD stage categories and gender. Chest 2007;132:1204-1211 doi:10.1378/chest.07-0593
5. Kainu A, Lindqvist A, Sarna S, Lundback B, Sovijarvi A. FEV1 response to bronchodilation in an adult urban population. Chest 2008;134:387-393 doi:10.1378/chest.07-2207
6. Pellegrino R, Brusasco V, Viegi G, et al. Definition of COPD: based on evidence or opinion? Eur Respir J 2008;31(3):681-682 doi:10.1183/09031936. 00154307
7. Tashkin DP, Celli B, Senn S, et al. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15):1543-1554 doi:10.1056/NEJMoa0805800
8. Lee TA, Pickard AS, Au D, Bartle B, Weiss KB. Medication safety in COPD patients: The risk of mortality associated with treatment in veterans with newly diagnosed COPD. Annals Intern Med 2008;149:380-390
9. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. JAMA 2008;300(12):1439-1450 doi:10.1001/jama.300.12.1439
10. Macie C, Wookdrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. International J COPD 2008;3(1):1-7.
11. Enright P. Does screening for COPD by primary care physicians have the potential to cause more harm than good? Chest 2006;129(4):833-835 doi:10.1378/chest.129.4.833
12. Enright PL. GOLD stage I is not a COPD risk factor. Thorax 2007;62(12):1107. (Pubitemid 350206207)
13. Enright P, Quanjer P. Don't diagnose mild COPD without confirming airway obstruction after an inhaled bronchodilator. COPD 2007;4(2):89-90. doi:10.1080/15412550701341509 (Pubitemid 47164865)
14. Tønnesen P, Carrozzi L, Fagerstrom KO, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Resp J 2007;29(2):390-417. doi:10.1183/09031936.00060806 (Pubitemid 46231920)